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Abstract. This report demonstrates a T-cell receptor 
(Tcr) restriction fragment length polymorphism, defined 
by a Tcrb-V6.1 gene probe and Bgl II restriction enzyme, 
to be absolutely correlated with allelic variation in the 
coding sequence of a Tcrb-V6.1 gene. A pair of non-con- 
servative amino acid substitutions distinguish the Tcrb- 
V6.1 allelic variants. An association of this Tcrb-V6.1 
gene allelic variant with one form of juvenile rheumatoid 
arthritis (JRA) was established in a cohort of 126 patients. 
The association was observed in patients possessing the 
HLA-DQAI*0101 gene. Among HLA-DQA *0101 in- 
dividuals, 19 of 26 patients (73.1%) carried one particular 
Tcrb-V6.1 gene allele as opposed to 11 of 33 controls 
(33%; p<0.005).  Haplotypes carrying this HLA gene 
have previously been shown to confer increased risk for 
progression of arthritis in JRA. This demonstration of a 
disease-associated Tcrb-V gene allelic variant has not, to 
our knowledge, been previously reported and supports the 
contribution of polymorphism in the Tcr variable region 
genomic repertoire to human autoimmune disease. 
Introduction 
Data on many of the HLA associations with autoimmune 
diseases have suggested the presence of other genetic fac- 
tors, probably outside the major histocompatibility com- 
plex (MHC). The antigen-specific T-cell receptor (Tcr), 
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which recognizes antigen only in the context of HLA 
molecules, seems a likely source of such effects. Interest 
has therefore focused on the Tcr c~ chain (Tcra) and 3 
chain (Tcrb) genes. The human Tcrb gene complex is 
located on chromosome 7. Transcription of the polypep- 
tide follows rearrangement of discontinuous gene 
segments encoding variable (10, diversity (D), joining (J), 
and constant (C) regions in a manner analogous to the 
transcription of immunoglobulins. DNA sequence and 
Southern blot hybridization analyses have subdivided the 
Tcrb-V gene segments into 20 groups, or subfamilies, 
defined on the basis of nucleotide sequence homology 
(Barth et al. 1985). Each subfamily contains between one 
and ten members. Gene segments of different subfamilies 
are highly interspersed and may be spaced more than five 
kilobases (kb) apart (Lai et al. 1989). The c~ chain gene 
complex, located on chromosome 14, structurally 
resembles the 3 chain complex (Davis and Bjorkman 
1988). 
Several studies have reported Tcr gene restriction frag- 
ment length polymorphisms (RFLPs) in a variety of 
autoimmune disorders, but were limited to description of 
C region RFLPs which carried low relative risks 
(Millward et al. 1987; Demaine et at. 1989; Tebib et at. 
1990). Recent family studies, demonstrating lack of 
linkage disequilibrium between V and C region genes of 
both Tcra and Tcrb gene complexes (Charmley et al. 
1988; Charmley et al. ]990), indicate that further study 
should be directed primarily towards V region genes, 
because they are the genes that most directly influence an- 
tigen-MHC recognition. Tcr-V region genes may be 
studied indirectly by RFLP and directly by sequence- 
dependent methods. 
The present study has demonstrated the possible con- 
tribution of a Tcrb-V region RFLP to the inherited 
predisposition of a form of juvenile rheumatoid arthritis 
(JRA) for which HLA associations have been established. 
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T h e  a b s o l u t e  c o r r e l a t i o n  o f  th is  R F L P  w i t h  c o d i n g  se-  
q u e n c e  va r i ab i l i t y  in an  a d j a c e n t  Tcrb-V6.1 g e n e  has  b e e n  
d e m o n s t r a t e d .  F i n a l l y ,  a n d  m o s t  i m p o r t a n t l y ,  t h e  a s s o c i a -  
t ion  o f  a h u m a n  a u t o i m m u n e  d i s e a s e  w i t h  a l le l ic  s e q u e n c e  
v a r i a t i o n  in a v a r i a b l e  r e g i o n  o f  t he  T c r  /3 c h a i n  is 
d e m o n s t r a t e d .  
Materials and methods 
Patientpopulation. One hundred and twenty-six unrelated Caucasian pa- 
tients, well characterized with respect to HLA markers, were studied. 
All had early-onset pauciarticular juvenile rheumatoid arthritis (EOPA- 
JRA) as defined by the American College of Rheumatology criteria 
(Cassidy et al. 1986). Such patients are characterized by a pauciarticular 
onset (affecting four or fewer joints) in the first six months of disease, 
predominance of females (88%), presence of antinuclear antibody 
(ANA), and the development of a chronic form of iridocyclitis. All pa- 
tients had disease onset before the age of 8 years. The control group 
of 207 unrelated Caucasian individuals resembled the disease population 
with respect to geographic and ethnic (European) origin, both carrying 
a strong Northern European (German) ethnic component. This control 
series has been described previously (Maksymowych et al. 1991). 
Tcrprobes. The human Tcrb cDNA clone 4D1, a 1 kb cDNA isolated 
from the human T-cell tumor line HPB-MLT, contains the V6.1, D, 
J, and C2 regions of the Tcrb chain (Jones et al. 1984; Leiden and Strom- 
inger 1986). This cDNA was subcloned in pUC19, and a specific V 
region probe was derived by polymerase chain reaction (PCR) amplifica- 
tion of the V region sequence using specific primers. The probe was 
labeled by random priming with [a-32p]-deoxynucleotide triphosphates 
(3000 Ci/mmol; New England Nuclear, Boston, MA) to specific ac- 
tivities ranging from 5 x 10 s to i x 109 cpm/~tg of DNA (Feinberg and 
Vogelstein 1983). 
Tcrb-V6.1 associated RFLP. This polymorphism was detected as 
previously described (Maksymowych et al. 1991). The Tcrb-V6.1/Bgl 
II probe/enzyme combination defines a bi-allelic locus with polymorphic 
bands of 12.5 and 5.7 kb. 
DNA amplification and sequencing. Bgl II restriction enzyme-digested 
genomic DNA, derived from five unrelated individuals homozygous for 
the 12.5 kb fragment and from five unrelated individuals homozygous 
for the 5.7 kb fragment, was run on agarose gels. Gel slices containing 
the polymorphic fragments were excised, isolated by phenol/chloroform 
extraction, and used as template for PCR amplification of the RFLP- 
related Tcrb-V6 gene member. The sequences of oligonucleotides to be 
used as Tcrb Vfi.  1 gene-specific primers were determined from the 
published sequence of the 4D1 eDNA that had served as the Tcrb-V6 
gene probe. The primers were derived from the 5' end and 3' end of 
the 4D1 cDNA V region sequence, (I. 5' CCGAATTCGATGG- 
GAGCTCAGGTGTGATC 3" sense; and II. 5' CCGAATTCACA- 
GAGATACACGGCTGAGTCC 3' antisense) so that the fragment 
amplified by these primers would include most of the exon encoding 
the Terb-V gene segment [223 base pair (bp)]. Reaction mixtures (100 
~tl) containing template DNA, oligonucleotide primers (1 gM), dNTPs 
(200 IxM) and 2,5 units of Taq I polymerase (Perkin-Elmer Cetus, Nor- 
walk, CT) were subjected in a thermal cycler (Perkin-Elmer Cetus) to 
30 cycles of denaturation (95 °C for 30 s), annealing (55 °C for 2 rain), 
and extension (72 °C for 45 s). PCR-amplified Tcrb V6 gene products 
were checked by 1.5 % agarose gel electrophoresis and ethidium bromide 
staining. Negative control samples were run with every PCR reaction. 
PCR reaction products were digested with Eco RI restriction enzyme 
(Pharmacia, Piscataway, NJ) in agarose (to cleave the 5' ends of the 
primers) and extracted with phenol/chloroform. The digested DNA was 
ligated into an Eco RI-digested M13 mpl9 vector, transformed into 
Escherichia coil JM109, and plated. Clones were screened by in situ 
plaque hybridization with the random-primer 32p-labeled Tcrb-V6 
cDNA probe. Purified DNA from positive clones was sequenced by the 
dideoxy chain termination method (Sequenase, US Biochemicals, 
Cleveland, OH). All sequences were determined on both strands. At 
least three clones per DNA restriction fragment were sequenced in order 
to confirm sequence variation. 
Dot-blot analysis. Members of the patient and control populations (pa- 
tients n=  83, controls n = 99) were oligotyped for Tcrb-V6.1 gene allelic 
sequence variants. After PCR amplification of 1 ~tg of genomic DNA 
using Tcrb-V6 gene specific primers, 2 ~tl of the amplified material was 
dot-blotted onto Nylon-66 membrane filters (0.1 ~tm pore size) 
(Schleicher and Schuell, Keene, NH). The following Tcrb-V6.1 gene 
allele-specific oligonucleotide (ASO) probes were synthesized (III. 5" 
CTGCCCAACGATCGGTT 3' and IV. 5' CACAGAGCGGGGG- 
GACT 3' designated V6.1N and V6.1R respectively detecting sequence 
V6.1A. Two other probes (V.) 5" CTGCCCAAAGATCGGTT 3' and 
VI. 5' CACAGAGCAGGGGGACT 3' were designated V6.1K and 
V6.1Q, respectively and detected sequence V6. IB. These probes were 
labeled with [a-32P]-ATP and polynucleotide kinase and hybridized 
with the blots overnight at 37 °C in 6 × standard sodium citrate (SSC), 
1 ×Denhardt's solution and 50 ~tg/ml low relative mass DNA. Blots 
were washed twice in 6 × SSC at room temperature, and 5 rain at 57 °C 
for probe III, at 53 °C for probe IV, at 55 °C for probe V, and at 49 °C 
for probe VI, followed by exposure to Kodak X-omat film for 2 h. 
Positive and negative controls consisted of PCR-amplified genomic 
DNA from individuals homozygous for either the 5.7 kb or the 12.5 
kb Bgl II fragment, whose Tcrb-V6.1 gene alleles had been characterized 
previously by DNA sequencing and dot-blot analysis. Additional con- 
trois included phage supernatants, each sample containing a different 
Tcrb-V6.1 gene allele. 
HLA typing, HLA-DR antigens in our entire study population were typed 
serologically according to standard techniques using antisera that includ- 
ed those tested by the eighth, ninth, and tenth Histocompatibility 
Workshops (Mittal et al. 1968). In addition, a previous study which in- 
cluded some subjects evaluated in the present study, had identified HLA- 
DQAl*0101 individuals as a distinct cohort of patients at increased risk 
for progression of polyarticular joint disease and a lower risk for the 
iridocyclitis of JRA (Van Kerckhove et al. !991). HLA-DQwl a-chain 
alleles were therefore typed using allele-specific oligonucleotide probes 
following PCR amplification of the second exon of the DQ c~-chain using 
specific primers (Van Kerckhove et al. 1991). Typing results were 
available for 121 patients with EOPA-JRA and 202 controls. 
Statistics. Statistical analysis was carried out using the chi-square test 
with one degree of freedom unless otherwise specified with adjustments 
for the number of comparisons made. P values were adjusted for multiple 
comparison using the Bonferroni correction. 
Results 
Tcrb-Vb gene R F L P ,  H L A  and disease. T h e  d i s t r i b u t i o n  
o f  Tcrb-V6.1 /Bgl  II R F L P  g e n o t y p e s  a n d  a l le l ic  f r e q u e n -  
c ies  d id  n o t  d i f f e r  s i gn i f i c an t l y  b e t w e e n  the  to ta l  p a t i e n t  
a n d  c o n t r o l  p o p u l a t i o n s  (X2 = 1 .24 ;  p > 0 .1 ,  2 d e g r e e s  o f  
f r e e d o m ;  T a b l e  1). H o w e v e r ,  c o m p a r i s o n s  m a d e  in  t h e  
c o n t e x t  o f  H L A  t y p e  r e v e a l e d  tha t  HLA-DQAI*OIO1  p a -  
t i en t s  d i f f e r e d  s i g n i f i c a n t l y  in  t h e i r  g e n o t y p e  d i s t r i b u t i o n  
f r o m  HLA-DQAI*OIO1  c o n t r o l s ,  e v e n  a f t e r  a d j u s t m e n t  
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Tab le  1. Tcrb-V6.1/Bgl II RFLP genotypes in patients with EOPA-JRA 
and controls 
RFLP genotype frequencies (n) 
Subjects 5.7/5.7 5.7/12.5 12.5/12.5 
Total patients 
( n=  126) 0.47 (59) 0.42 (53) 0.11 (14) 
Total controls 
(n=207)  0.51 (105) 0.42 (86) 0.08 (16) 
DQAI*0101 Patients 
(n=28)  0.25 (7) 0.57 (16) 0.18 (5) 
DQAI*0101 Controls 
(n=33)  0.67 (22) 0.30 (10) 0.03 (1) 
for the 15 comparisons made (X2=11.48; 2 degrees of 
freedom, p = 0.003, pcorr = 0.045). HLA-DQA1 "0101 pa- 
tients had a higher frequency of the 12.5 kb Bgl II frag- 
ment (26 of 56 alleles) than did either HLA-DQA1*0101 
controls (12 of 66 alleles; X2=11.12; p=0.00085; 
pcorr=0.01) or HLA-DQA1*0101 negative patients (48 
of 186 alleles; X2=8.62; p=0.003; pcorr=0.045; Table 
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Tab le  2. Tcrb-V6.1/Bgl II RFLP allele frequencies in DQAI*0101 
positive and negative patients and controls. 
Subjects Number of  alleles in each category 
Patients 12.5 5. 7 Total 
DQAI*OIO1 + 26 30 56 
DQAI*OIO1 - 48 138 186 
Controls 
DQA1 "0101 + 12 54 66 
DQAI*OIO1 103 235 338 
2). Overall, 21 of the 121 patients who were HLA typed 
(17.4%) carried both the HLA-DQAI*OIO1 allele and a 
12.5 kb Bgl II fragment compared to 11 of the 191 
HLA-typed controls (5.5%; X2=10.82; p=0.001; 
pcorr=0.008), conferring a relative risk for disease of 
3.65. 
Sequence variation in the Tcrb-V6.1 gene. The five in- 
dividuals who were homozygous for the 12.5 kb polymor- 
phic fragment and the five who were homozygous for the 
Nucleotide Sequence 
V6.1A CCA ATT TCA GGT CAT ACT GCC CTT TAC TGG TAC CGA CAA A G C  CTG GGG CAG GGC CCA GAG TTT CTA ATT TAC TTC CAA 
V6.1B . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
GGC ACG GGT GCG GCA GAT GAC T C A  GGG CTG C C C  AAC GAT CGG TTC TTT GCA GTC A G G  CCT G A G  G G A  T C C  GTC TCT ACT CTG 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
AAG ATC C A G  C G C  ACA G A G  CGG GGG G A C  T C A  GCC GTG T A T  C T C  TGT GCC 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Amino Acid Sequence (Predicted) 
V6.1A Pro Ile Ser Gly His Thr Ala Leu Tyr Trp Tyr Arg Gin Ser Leu Gly Gin Gly Pro Glu Leu Leu tie Tyr Phe Gin Gly Thr Gly AIa Ala Asp Asp Ser Gly 
V6.1B . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Leu Pro Asn Asp Arg Phe Phe Ala Val Arg Pro Gin Gly Set Val Set Thr Leu Lys Ile Gin Arg Thr Gin Arg Gly Asp Ser Ala Val Tyr Leu Cys Ala 
. . . . . . .  Lys . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  Gin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Fig.  1. Tcrb-V6.1 gene and derived amino acid sequences following PCR amplification from Bgl II restriction fragment (12.5 kb, 5.7 kb) templates. 
The oligonucleotides and amino acids dist inguishing V6.1A and B alleles are shown (positions 62 and 84). 
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5.7 kb polymorphic fragment (see Materials and methods) 
yielded 47 and 23 Tcrb-V6 gene clones, respectively, after 
PCR amplification and m13 subcloning. DNA sequence 
data obtained from these clones revealed two Tcrb- 
V6. lgene sequences, V6.1A and V6.1B (Fig. 1). Sequence 
V6.1B has not, to our knowledge, been described 
previously. It differs from sequence V6.1A by two single 
bp substitutions, an adenine for a cytosine at position 132 
of the amplified fragment and an adenine for a guanine 
at position 197 of the amplified fragment. These substitu- 
tions occurred as paired changes in all 70 clones examin- 
ed. Since the 4D 1 cDNA is a partial length clone lacking 
54 nucleotides at the 5' end of the Vgene coding sequence, 
these changes would result in substitution of a lysine 
(AAA) for an asparagine (AAC) at position 62 of the Tcr 
[3 chain and a glutamine (CAG) for an arginine (CGG) 
at position 84 of the Tcr [3 chain. Neither change results 
in the creation of a new Bgl II restriction site. 
A) 
1 2 3 4 5 6 7 8 9 10 
A O 0  • O O O O 0  O o  
B O 0  O 0  O I  O 0  
Dot Blot Probed with ASO probe III (6.1A sequence) 
B) 
1 2 3 4 5 6 7 8 9 10 
A 
B O 0  O 0  
Dot Blot Probed with ASO probe IV (6.1B sequence) 
Correlation of allelic sequence variation with Tcrb-V6.1 
gene RFLP. The sequence data obtained from clones 
allowed the design and use of allele-specific 
oligonucleotide (ASO) probes that hybridized to regions 
spanning the newly identified substitutions (Fig. 1) thus 
distinguishing sequences V6.1A and B. In view of 
previous reports documenting frequent recombination 
within the Tcra and b-V regions (Seboun et al. 1989; 
Charmley et al. 1990) such oligonucleotide probes were 
initially used to ascertain the correlation between the Tcrb- 
V6.1/Bgl II RFLP and the two V6.1 gene sequences in 
individuals carrying different RFLP genotypes. PCR- 
amplified genomic DNA samples were initially analyzed 
with the V6.1 N and K probes defining sequences V6.1A 
and B, respectively (see Materials and methods). Samples 
from all individuals homozygous for the 5.7 kb Bgl II frag- 
ment (patient n = 38; control n = 28) hybridized only to the 
V6.1N probe indicating the presence of sequence V6.1A, 
while samples from all 12.5 kb homozygotes (patients 
n= 14; controls n= 16) hybridized only to the V6.1Kpro- 
bes, indicating the presence of sequence V6.1B (Fig. 2). 
Additional individuals, heterozygous at the Bgl II RFLP 
locus (patient n = 37; control n = 34), were oligotyped and 
shown to possess both Tcrb V6.1 sequence variants. Tcrb 
V6.1A and Vg. 1B therefore represent allelic variants that 
correlate absolutely with the 5.7 kb and 12.5 kb Bgl II 
RFLP alleles, respectively. 
Results obtained with the V6.1N and V6.1K probe pair 
were verified in additional dot-blot analyses on 36 
samples, using the V6.1R and V6.1Q probes (Fig. 1). 
Tcrb-V6.1 allelic sequence variations and disease. The 
V6.1B gene was present in 19/26 HLA-DQAI*OIO1 pa- 
tients, compared with 11/33 of the HLA-DQAI*OIO1 con- 
trols (X2=9.19; p=.001). 





5.7 Kb homozygotes 
5.7/12.5 Kb heterozygotes 
12.5 Kb homozygotes 
5.7 Kb positive 
sequence clones 
Discussion 
This study demonstrates the association of a Tcrb V region 
gene polymorphism with one subtype of JRA in the con- 
text of a particular HLA class II allele, HLA-DQAl*0101. 
These findings thus support a possible contribution by this 
Tcrb-V gene to at least one human autoimmune disease, 
EOPA-JRA. 
Sequence data obtained on PCR-amplified DNA deriv- 
ed from restriction fragment templates that contain Tcrb 
V6.1 genes, indicated proximity of the Bgl II RFLP to a 
V6.1 gene locus containing two V6.1 gene allelic variants. 
One such variant, V6.1B, represents a previously 
undescribed V6.1 gene sequence. 
Comparison of the V6.1A and B gene sequences in- 
dicates a high degree of sequence conservation, consistent 
with two previous reports. Robinson (1989) described a 
single bp substitution within the coding region of the Tcrb 
V1 gene, and Li and co-workers (1990) reported two bp 
substitutions in the coding region of the Tcrb-V6. 7 gene. 
Additional sequence variability of the V6.1 gene at the ex- 
treme 5' and 3' ends cannot be excluded however. The 
4D1 cDNa (Leiden and Strominger 1986) used as the Tcrb 
V6.1 gene probe in the present study is a partial length 
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clone, lacking 54 nucleotides at the 5' end of the coding 
region sequence. Furthermore, the 3' V6.1 gene primer 
annealed to the 4D1 cDNA template nine nucleotides 
upstream of the V-D region junction. Sequences at the ex- 
treme 5' and 3' ends of the V6.1 gene coding sequence 
were therefore not included in our PCR-amplified frag- 
ment. However, the finding of only two V6.1 gene alleles 
is consistent with previous studies demonstrating limited 
allelism in human and murine Tcr-V genes (Robinson 
1989; Li et al. 1990; Pullen et al. 1990; Posnett 1990). 
The similarities between framework regions of Tcr 
molecules and immunoglobulins permit the construction 
of structural models of the Tcr molecule based on known 
immunoglobulin structure (Chothia et al. 1988). The two 
nucleotide differences between allelic variants V6.1A and 
V6.1B result in non-conservative amino acid substitutions 
at positions 62 and 84 of the Tcrb chain. Both positions 
represent sites of intermediate residue variability and each 
appears to be located in the loops between b-sheet 
framework strands. Position 62 is thought to lie close to 
the Tcr equivalent of the second hypervariable region of 
Ig(Davis and Bjokman 1988) and therefore may influence 
antigen/MHC recognition. 
Consideration of the role played by Tcrb-V6.1 genes 
in the pathogenesis of EOPA-JRA must include the obser- 
vation that HLA-DQAl*0101_ patients are more likely to 
possess a V6.1B gene and less likely to possess a V6.1A 
gene in their genomic repertoire. A possible etiologic role 
for the V6.1B allele in disease susceptibility would be con- 
sistent with previous reports assigning a dominant role for 
T cells expressing particular variable genes in animal 
models of autoimmunity (Urban et al. 1988; Acha-Orbea 
et al. 1988). Alternatively, the decreased frequency of the 
V6.1A gene segment in HLA-DQAl*0101 patients could 
represent a "hole"  in the available Tcr repertoire. In- 
dividuals lacking the V6.1A gene segment may be unable 
to eliminate foreign antigen(s) presented by HLA- 
DQAI*0101; the antigen(s) may then act as an inciting 
arthritogen. Another possibility consistent with the con- 
cept of a "hole in the repertoire" is that the V6.1A gene 
segment encodes a suppressor receptor on T cells. Several 
epitopes derived from type II collagen have been shown 
to stimulate suppressor T cells that confer protection 
against murine collagen-induced arthritis (Myers et al. 
1989). Such suppressor T cells may be necessary to pre- 
vent establishment of chronic disease following the in- 
citing antigenic stimulus or to prevent progression of 
disease to a polyarticular form. 
These considerations do not adequately account for the 
occurrence of disease in HLA-DQAI*OI01 individuals 
who are either heterozygous for the V6.1 gene alleles or 
homozygous for V6.1A. HLA (Gulwani-Akolkar et al. 
1991) and non-HLA influences on thymic selection of ex- 
pressed Tcrs in the periphery may result in preferential 
expression of V6.1B rather than V6.1A in heterozygotes. 
Thus, HLA-DQAI*OI01, additional HLA alleles, non- 
HLA alleles, and/or endogenous superantigens on thymic 
epithelial cells could positively select T cells bearing 
V6.1B in preference to V6.1A or, alternatively, could pre- 
vent the maturation of T cells bearing V6.1A (if such T 
cells are potentially self-reactive; Zhou et al. 1991). Addi- 
tional considerations, of particular relevance to V6.1A 
homozygotes, are the possible contributory roles of addi- 
tional Tcrb- V gene segments, of Tcra- V genes, and of se- 
quence variation in the D and J regions of the Tcr/3 chain. 
Other reports support the suggestion that gene com- 
plementation between Tcrb-V genes and HLA-DQ alleles 
may contribute to disease chronicity in arthritis patients. 
In the murine model of collagen arthritis, development 
of disease is dependent on the presence of a Tcr haplotype 
carrying a full complement of Tcrb V genes and an allelic 
variant of the I-A chain carried on the H2 q haplotype 
(Banerjee et al. 1988; Holmdahl et al. 1989). The concept 
of Tcr/HLA gene complementation has also received ex- 
perimental support from studies of animal models of 
systemic lupus (Yanagi et al. 1986; Ghatak et al. 1987) 
and of a subgroup of systemic lupus erythematosus (SLE) 
patients with anti-Ro antibodies (Frank et al. 1990). 
The advantage of segregating patients on an im- 
munogenetic basis was supported by our ability to isolate 
individuals who were at increased risk of suffering pro- 
gressive disease. Further insight into immunopathologic 
mechanisms will require studies of Tcr expression in 
diseased tissue. Such investigation may provide the ra- 
tionale for the development of highly specific im- 
munotherapeutic strategies based on Tcr epitope-specific 
reagents. 
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